# The state of cancer care in Venezuela: interviews with Venezuelan oncologists, 2019

Source: https://onco.cc/key-papers/paper-duma-state-of-cancer-care-venezuela-jgo-2019/  
OnCo record `paper-duma-state-of-cancer-care-venezuela-jgo-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Two Venezuelan doctors interviewed oncologists in and outside Venezuela and reported shortages of cancer medicines and opioids, radiotherapy machines out of service, and oncologists leaving the country.

## Summary

Published as "The State of Cancer Care in Venezuela", a commentary by Narjust Duma (Mayo Clinic) and Liseth Duque Duran (Hospital Dr. José María Vargas de Caracas) built on interviews with Venezuelan surgical and medical oncologists. The authors note that data on cancer care in Venezuela were difficult to find and that the health ministry had published bulletins sporadically, if at all, for several years.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Journal of Global Oncology
- Year: 2019
- DOI: 10.1200/JGO.19.00031
- Authors: Duma N, Duque Duran L
- Findings: Interviewed oncologists dated the worsening of medicine shortages to 2010, starting with tyrosine kinase inhibitors; in 2019 cisplatin and bevacizumab were short, and the authors cite an estimate that Venezuela had 10% of the drugs needed for cancer care.; Supply of aromatase inhibitors and tamoxifen fluctuated, so breast cancer patients could be switched between hormonal medicines within their first year of adjuvant treatment.; Radiation machines in public and private hospitals were often broken and abandoned for lack of supplies, technicians and physicians, and many breast cancer patients had mastectomy with extensive node dissection because adjuvant radiotherapy was unavailable.; Hospital Dr. José María Vargas de Caracas had empty fellowship places in surgical and medical oncology for the first time.
- What it means: A first-hand account of what shortages meant for treatment choices in 2019, at a time when official figures were not being published; it is evidence of conditions then, not a measurement of them now.
- Caveats: A commentary based on interviews, not a survey or registry study.; The figures it quotes come from its cited sources, not from its own data collection.; Describes 2019; the situation may have changed since.

## Sources

- J Glob Oncol 2019: https://doi.org/10.1200/JGO.19.00031
- PubMed: https://pubmed.ncbi.nlm.nih.gov/31050921/
- Full text (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC6550090/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Anastrozole](https://onco.cc/drugs/anastrozole/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- institutions: [Ministerio del Poder Popular para la Salud (Venezuela)](https://onco.cc/institutions/venezuela-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/paper-duma-state-of-cancer-care-venezuela-jgo-2019.json